Immunohistochemical profile of intravenous leiomyomatosis

To determine the immunohistochemical staining profile of intravenous leiomyomatosis (IVL), we analysed six IVLs and 12 ordinary leiomyomas (LM) for immunoreactivity with a panel of 11 antibodies. All IVLs and LMs reacted with antibodies to alpha-smooth muscle actin (alphasm), h caldesmon, vimentin and progesterone receptor (PR). Five of six IVLs and all LMs reacted with desmin. All IVLs were negative for CD-10. Only one LM exhibited focal CD-10 positivity. Three of six IVLs and nine of 12 LMs showed estrogen receptor expression. All IVLs and LMs showed immunnegativity with MIB-1 and inhibin. There were not any significant differences between immunoreactivity patterns of IVL and LM for asm, desmin, h caldesmon, CD-10, MIB-1 and PR. We conclude that, although they appear to be useful markers in differentiating IVL from ESS and LMS, a larger study also including ESS and LMS would be necessary to confirm their validity.

Endometrial stromal sarcoma; MIB-1; Estrogen receptor; Progesterone receptor

[1] Clement P.B.: "Intravenous leiomyomatosis of the uterus". Pathol. Annual., 1988, 23, 153.

[2] Heinonen P.K., Taina E., Nerdrum T. et al.: "Intravenous Ieiomyomatosis". Ann. Chir. Gynaecol., 1984, 73, 100.

[3] Tierney W.M., Ehrlich C.E., Bailey J.C., King R.D.. Roth L.M., Wann S.: "Intravenous leiomyomatosis of the uterus with extension into the heart". Am. J. Med., 1980, 69, 471.

[4] Matsumoto K., Yamamoto T., Hisayoshi T., Asano G.: "Intravenous leiomyomatosis of the uterus with multiple pulmonary metastases associated with large bullae-like cyst formation". Pathol. Int., 2001, 51, 396.

[5] Mitsuhaski A., Nagai Y., Sugita M., Nakajima N., Sekiya S.: "GnRH agonist for intravenous leiomyomatosis with cardiac extension. A case report". J. Reprod. Med., 1999, 44, 883.

[6] Kokawa K., Yamoto M., Yata C., Mabuchi Y., Umesaki N.: "Postmenopausal intravenous leiomyomatosis with high levels of estradiol and estrogen receptor". Obstet. Gynecol., 2002, 100, 1124.

[7] Diakomanolis E., Elsheikh A., Sotiropoulou M. et al.: "Intravenous leiomyomatosis". Arch. Gynecol. Obstet., 2003, 267, 256.

[8] Oliva E., Young R.H., Amin M.B., Clement P.B.: "An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus. A study of 54 cases emphasizing the importance of using a panel because overlap in immunreactivity for individual antibodies". Am. J. Surg. Pathol., 2002, 26, 403.

[9] Norris H.J., Parmley T.H.: "Mesenchymal tumors of the uterus. (V) Intravenous leiomyomatosis: A clinical and pathologic study of 14 cases". Cancer, 1975, 36, 2164.

[10] Carcangiu M.L., Chambers J.T.,V oynick I.M., Pirro M.,S chwartz P.E.: "Immunohistochemical evaluation of estrogen and progeserone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations". Am. J. Clin. Pathol., 1990, 94, 247.

[11] Popiolek D., Yee H., levine P., Vamvakas E., Demopoulos R.I.: "MIB I as a possible predictor of recurrence in low-grade endometrial stromal sarcoma of the uterus". Gynecol. Oneal., 2003, 90, 353.

[12] Mulvany N.J., Slavin J.L., Ostor A.G., Fortune D.W.: "Intravenous leiomyomatosis of the uterus: a clinicopathologic study of 22 asces". Int. J. Gynecol. Pathol., 1994, 13, 1.

[13] Clemet P.B.,Y oung R.H., Scully R.E.: "Intravenous leiomyomatosis of the uterus. A clinicopathological analysis of 16 cases with unusual histologic features". Am. J. Surg. Pathol., 1888, 12, 932.

[14] Amadra S., Nakano H., Tsuneyoshi M.: "Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p 53 expression, DNA flow cytometry, and muscle specific actins". Int. J. Gynecol. Pathol., 1995, 14, 134.

[15] Yavuz E., Giilliioglu M.G., Akbas N. et al.: "The value of intratumoral mast count and Ki-67 immunoreactivity index in differential diagnosis of uterine smooth muscle neoplasms". Pathol. Int., 2001, 51,938.

[16] Zhai Y.L., Kobayashi Y., Mori A. et al.: "Expression of steroid receptors, Ki-67 and p 53 in uterine leiomyosarcomas". Int. J. Gynecol. Pathol., 1999, 18, 20.

[17] Mittal K., Demopoulos R.I.: "MIB-1 (Ki-67), p 53, estrogen receptor and progesterone receptor expression im uterine smooth muscle tumors". Hum. Pathol., 2001, 32, 984.

[18] McClugage W.G.: "Value of inhibin staining in gynecological pathology". Int. J. Gynecol. Pathol., 2001, 20, 79.